tg therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for b-cell malignancies and autoimmune diseases. currently, the company is developing two therapies targeting hematological malignancies. tg-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the cd20 antigen found on mature b-lymphocytes. tg therapeutics is also developing tgr-1202, an orally available pi3k delta inhibitor. the delta isoform of pi3k is strongly expressed in cells of hematopoietic origin and is believed to be important in the proliferation and survival of b-lymphocytes. both tg-1101 and tgr-1202 are in clinical development for patients with hematologic malignancies. the company also has pre-clinical programs to develop irak4 inhibitors, and anti-pd-l1 and anti-gitr antibodies. tg therapeutics is headquartered in new york city and is traded on nasdaq under the ticker symbol "tgtx".
Company profile
Ticker
TGTX
Exchange
Website
CEO
Michael Weiss
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
ATLANTIC PHARMACEUTICALS INC, ATLANTIC TECHNOLOGY VENTURES INC, MANHATTAN PHARMACEUTICALS INC
SEC CIK
Corporate docs
Subsidiaries
Ariston Pharmaceuticals, Inc. • TG Biologics, Inc. • TG Therapeutics AUS Pty Ltd • TG Cell Therapy, Inc. ...
IRS number
363898269
TGTX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
29 Feb 24
8-K
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results
28 Feb 24
8-K
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anticipated Milestones
10 Jan 24
10-Q
2023 Q3
Quarterly report
6 Nov 23
8-K
TG Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
1 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
TG Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
1 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
15 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
DEFA14A
Additional proxy soliciting materials
1 May 23
Transcripts
TGTX
Earnings call transcript
2023 Q4
28 Feb 24
TGTX
Earnings call transcript
2023 Q3
1 Nov 23
TGTX
Earnings call transcript
2023 Q2
1 Aug 23
TGTX
Earnings call transcript
2023 Q1
1 May 23
TGTX
Earnings call transcript
2022 Q4
28 Feb 23
TGTX
Earnings call transcript
2022 Q3
12 Nov 22
TGTX
Earnings call transcript
2022 Q2
8 Aug 22
TGTX
Earnings call transcript
2021 Q4
1 Mar 22
TGTX
Earnings call transcript
2021 Q3
5 Nov 21
TGTX
Earnings call transcript
2021 Q2
2 Aug 21
Latest ownership filings
4
Sagar Lonial
15 Mar 24
4
Laurence N Charney
13 Mar 24
144
Notice of proposed sale of securities
13 Mar 24
144
Notice of proposed sale of securities
12 Mar 24
5
Sean A Power
14 Feb 24
SC 13G/A
Darwin Global Management, Ltd.
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
BlackRock Inc.
26 Jan 24
SC 13G/A
STATE STREET CORP
25 Jan 24
4
Laurence N Charney
8 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 152.18 mm | 152.18 mm | 152.18 mm | 152.18 mm | 152.18 mm | 152.18 mm |
Cash burn (monthly) | (no burn) | (no burn) | (no burn) | 1.58 mm | (no burn) | 3.51 mm |
Cash used (since last report) | n/a | n/a | n/a | 10.47 mm | n/a | 23.26 mm |
Cash remaining | n/a | n/a | n/a | 141.71 mm | n/a | 128.93 mm |
Runway (months of cash) | n/a | n/a | n/a | 89.8 | n/a | 36.8 |
Institutional ownership, Q3 2023
58.1% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 233 |
Opened positions | 43 |
Closed positions | 58 |
Increased positions | 100 |
Reduced positions | 51 |
13F shares | Current |
---|---|
Total value | 747.08 bn |
Total shares | 89.71 mm |
Total puts | 2.13 mm |
Total calls | 1.80 mm |
Total put/call ratio | 1.2 |
Largest owners | Shares | Value |
---|---|---|
Vanguard | 13.47 mm | $112.62 bn |
BLK Blackrock | 9.99 mm | $83.49 bn |
STT State Street | 9.82 mm | $82.08 bn |
Paradigm Biocapital Advisors | 3.62 mm | $30.25 bn |
Wellington Management | 3.10 mm | $25.89 bn |
Geode Capital Management | 2.93 mm | $24.53 bn |
Soleus Capital Management | 2.88 mm | $24.11 bn |
Two Sigma Investments | 2.34 mm | $19.57 bn |
Millennium Management | 2.02 mm | $16.86 bn |
Opaleye Management | 1.89 mm | $15.80 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
13 Mar 24 | Sagar Lonial | Common Stock | Sell | Dispose S | No | No | 15.935 | 5,000 | 79.68 k | 108,878 |
12 Mar 24 | Charney Laurence N | Common Stock | Sell | Dispose S | No | No | 15.97 | 22,000 | 351.34 k | 215,229 |
6 Jan 24 | Weiss Michael S | Common Stock | Grant | Acquire A | No | No | 0 | 1,001,908 | 0.00 | 13,074,929 |
5 Jan 24 | Charney Laurence N | Common Stock | Sell | Dispose S | No | No | 19.03 | 17,500 | 333.03 k | 237,229 |
15 Dec 23 | Power Sean A | Common Stock | Gift | Dispose G | No | No | 0 | 40,000 | 0.00 | 641,969 |
News
TG Therapeutics Inc Awarded $186,776,520 Contract From Department Of Veterans Affairs, NAC Pharmaceuticals For Pharmaceutical Preparation Manufacturing 6505--Anti CD20 Antibodies
17 Apr 24
(TGTX) - Analyzing TG Therapeutics's Short Interest
13 Mar 24
HC Wainwright & Co. Reiterates Buy on TG Therapeutics, Maintains $45 Price Target
1 Mar 24
Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $13
29 Feb 24
Why Bumble Shares Are Trading Lower By 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
28 Feb 24
Press releases
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
18 Apr 24
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
15 Apr 24
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
27 Mar 24
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
8 Mar 24
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
1 Mar 24